On the chart you can see the default numbers in dynamics for Yifan Pharmaceutical Co., Ltd. (002019.SZ). Companys revenue shows the average of 1939.694 M which is 0.195 % gowth. The average gross profit for the whole period is 878.093 M which is 0.300 %. The average gross profit ratio is 0.392 %. The net income growth for the company last year performance is -5.334 % which equals 6.657 % % on average for the whole company history.,
Diving into the fiscal trajectory of Yifan Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.083. In the realm of current assets, 002019.SZ clocks in at 3251.143 in the reporting currency. A significant portion of these assets, precisely 773.378, is held in cash and short-term investments. This segment shows a change of -0.376% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 718.463, if any, in the reporting currency. This indicates a difference of 19.508% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 812.043 in the reporting currency. This figure signifies a year_over_year change of -0.077%. Shareholder value, as depicted by the total shareholder equity, is valued at 8275.634 in the reporting currency. The year over year change in this aspect is -0.061%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 1390.536, with an inventory valuation of 928.61, and goodwill valued at 2737.42, if any. The total intangible assets, if present, are valued at 2605.59. Account payables and short-term debt are 431.36 and 1116.42, respectively. The total debt is 1995.19, with a net debt of 1296.82. Other current liabilities amount to 506.35, adding to the total liabilities of 3144.93. Lastly, the referred stock is valued at 0, if it exists.
The financial landscape of Yifan Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -1.154. The company recently extended its share capital by issuing 0.85, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -670165050.310 in the reporting currency. This is a shift of 0.320 from the previous year. In the same period, the company recorded 228.43, 6.46, and -1880.31, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -86.38 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 2006.74, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Yifan Pharmaceutical Co., Ltd.'s revenue saw a change of 0.048% compared with the previous period. The gross profit of 002019.SZ is reported to be 1830.89. The company's operating expenses are 1821.44, showing a change of 19.441% from the last year. The expenses for depreciation and amortization are 228.43, which is a 0.225% change from the last accounting period. Operating expenses are reported to be 1821.44, which shows a 19.441% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.976% year-over-year growth. The operating income is 9.45, which shows a -0.976% change when compared to the previous year. The change in the net income is -5.334%. The net income for the last year was -551.07.
